TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00728429

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise intervention
Description: 24 week program of exercise
Study: NCT01287104

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Natural Killer (NK) Cell Infusion
Description: Post-transplant Day 21 (plus-minus 3 days): (1 x 10(5), 1 x 10(6) or 1 x 10(7) natural killer (NK) cells/kg by intravenous (IV) infusion. Followed by a second NK cell infusion of the same cell dose, on Day 49 plus-minus 7 days.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem Cell Infusion
Description: Transplant Day 0: \>4 x 10(6)/kg cluster of differentiation 34 (CD34)+ stem cells by IV infusion Filgrastim, 5 microgram/kg per day subcutaneous (SQ) from day 0 until absolute neutrophil count (ANC) \>5000/microliters x2
Study: NCT03835663

Intervention type: DIAGNOSTIC_TEST
Intervention: No intervention but patients are undergoing an upper GI endoscopy and biopsies for clinical purposes
Description: Standard upper GI endoscopy with biopsies

Intervention type: DIAGNOSTIC_TEST
Intervention: No intervention but patients are undergoing an upper GI endoscopy and biopsies for clinical purposes
Description: Standard upper GI endoscopy with biopsies

Intervention type: DIAGNOSTIC_TEST
Intervention: No intervention but patients are undergoing an upper GI endoscopy and biopsies for clinical purposes
Description: Standard upper GI endoscopy with biopsies
Study: NCT04319848

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TE-EK treatment group
Description: Transplantation of tissue-engineered endothelial graft through DSAEK procedure.
Study: NCT00098787

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV
Study: NCT03806946

Intervention type: DIAGNOSTIC_TEST
Intervention: electroencephalography
Description: diagnosis epileptic discharge

Intervention type: DIAGNOSTIC_TEST
Intervention: psychometric scales to diagnosis psychiatric disorders
Description: to diagnosis intellectual disability, attention deficit hyperactivity disorder ,epilepsy,autism and other mental illness.
Study: NCT03141671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone is a corticosteroid. It prevents the release of substances in the body that cause inflammation. It also suppresses the immune system.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: -blocks the function of hormones including testosterone which prostate cancer uses to grow and spread
Study: NCT03600480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0174-0833
Description: Participants will receive increasing dose levels of 0.16 mg, 0.3 mg, 0.6 mg, 1.2 mg, 2.4 mg or 4.5 mg of NNC0174-0833 (subcutaneous \[s.c.\], in a lifted fold of the abdominal skin) injection once weekly starting with a very low dose and then escalated every 4 weeks to a slightly higher dose each time. Each participant will only be given one dose level.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Participants will receive 2.4 mg of semaglutide (s.c., in a lifted fold of the abdominal skin) injection once weekly starting with a very low dose and then escalated every 4 weeks to a slightly higher dose each time.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide
Description: Participants will receive 2.4 mg of semaglutide (s.c., in a lifted fold of the abdominal skin) injection once weekly starting with a very low dose and then escalated every 4 weeks to a slightly higher dose each time.
Study: NCT03806946

Intervention type: DIAGNOSTIC_TEST
Intervention: psychometric scales to diagnosis psychiatric disorders
Description: to diagnosis intellectual disability, attention deficit hyperactivity disorder ,epilepsy,autism and other mental illness.

Intervention type: DIAGNOSTIC_TEST
Intervention: psychometric scales to diagnosis psychiatric disorders
Description: to diagnosis intellectual disability, attention deficit hyperactivity disorder ,epilepsy,autism and other mental illness.

Intervention type: DIAGNOSTIC_TEST
Intervention: psychometric scales to diagnosis psychiatric disorders
Description: to diagnosis intellectual disability, attention deficit hyperactivity disorder ,epilepsy,autism and other mental illness.

Intervention type: DIAGNOSTIC_TEST
Intervention: psychometric scales to diagnosis psychiatric disorders
Description: to diagnosis intellectual disability, attention deficit hyperactivity disorder ,epilepsy,autism and other mental illness.

Intervention type: OTHER
Intervention: psychometric scales for assesment socioeconomic and behaviour problems
Description: to assessment other behavioural comorbidity as aggression ,mood changes,etc and help in identify function impairment, social and economic burden

Intervention type: OTHER
Intervention: psychometric scales for assesment socioeconomic and behaviour problems
Description: to assessment other behavioural comorbidity as aggression ,mood changes,etc and help in identify function impairment, social and economic burden

Intervention type: OTHER
Intervention: psychometric scales for assesment socioeconomic and behaviour problems
Description: to assessment other behavioural comorbidity as aggression ,mood changes,etc and help in identify function impairment, social and economic burden
Study: NCT01435941

Intervention type: DRUG
Intervention: Non-steroidal anti-inflammatory drug (NSAID)
Description: Participants who self-report that they have treated headaches with any drug in the non-steroidal anti-inflammatory drug (NSAID) class

Intervention type: DRUG
Intervention: Triptan
Description: Participants who self-report that they have treated headaches with any drug in the NSAID class and any drug in the triptan class including naratriptan, sumatriptan, rizatriptan, frovatriptan, almotriptan, eletriptan, and zolmitriptan
Study: NCT03846479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itacitinib
Description: for up to 56 days
Study: NCT00098787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV
Study: NCT02747082

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Retreatment of root-filled teeth with infection
Description: Root-filled teeth with infection are being treated with either 1% NaOCl or 2% CHX as disinfection irrigation solution.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Retreatment of root-filled teeth with infection
Description: Root-filled teeth with infection are being treated with either 1% NaOCl or 2% CHX as disinfection irrigation solution.
Study: NCT02689622

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: research of disease-related factors
Description: included in IPSS and IPSS-R, lactate dehydrogenase, ferritin level, transfusion- dependence, molecular markers as genes mutations
Study: NCT01361711

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: alemtuzumab
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ofatumumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: Correlative studies
Study: NCT03253640

Intervention type: OTHER
Intervention: Exposure
Description: Healthcare associated infection (HAI)
Study: NCT03600480

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (NNC0174-0833)
Description: Participants will receive once weekly injections of NNC0174-0833 matched placebo.
Study: NCT01885052

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: QuitTXT Study
Description: Assess the efficacy of a 6-8 week text message program to help young adults quit smoking.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: QuitTXT Study
Description: Assess the efficacy of a 6-8 week text message program to help young adults quit smoking.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Low Contact
Study: NCT04013919

Intervention type: DRUG
Intervention: Multiple Daily Injections of Insulin
Description: Basal/ Bolus insulin injections

Intervention type: DRUG
Intervention: Multiple Daily Injections of Insulin
Description: Basal/ Bolus insulin injections

Intervention type: DRUG
Intervention: Single insulin injections
Description: Basal insulin injections only
Study: NCT03183037

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: The acupuncture group will undergo 8 weeks of outpatient acupuncture or sham acupuncture treatments (twice weekly for 2 weeks, then weekly for 6 weeks, 10 treatments in total). The investigators have designed this approach to standardize acupuncture treatment for future broad use; it is based on the understanding that CIPN is a global symptom complex rather than individual isolated or local symptoms.
Study: NCT02689622

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: research of comorbidities
Description: HCT-Comorbidity Index, MDS-Comorbidity Index, Adult Comorbidity Evaluation-27, Cumulative Illness Rating Scale-G

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical performance
Description: Activities of Daily Living and physical performance
Study: NCT01113749

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Feeding Options in Dementia Decision Aid
Description: Structured decision aid on feeding options in dementia care with prompting to share information in discussion with primary treating health care provider.
Study: NCT04244812

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moxibustion
Description: Two sessions of moxibustion will be performed in the Heart meridian and Lung meridian successively.~Intervention in the Heart meridian: moxibustion will be performed above Shaohai (HT3) for 15 minutes. During moxibustion, the probes of laser doppler flowmetry will detect the microcirculatory characteristics of three measuring sites, which include the midpoint of the Heart meridian along the left forearm, Chize (LU5) of the Lung meridian, and the midpoint of the Lung meridian along the left forearm.~Intervention in the Lung meridian: moxibustion will be performed above Chize (LU5) for 15 minutes. During moxibustion, the probes of laser doppler flowmetry will detect the microcirculatory characteristics of three measuring sites, which include the midpoint of the Lung meridian along the left forearm, Shaohai (HT3) of the Heart meridian, and the midpoint of the Heart meridian along the left forearm.

Intervention type: DEVICE
Group type: OTHER
Intervention: Laser doppler flowmetry
Description: Laser doppler flowmetry will be used to detect the microcirculatory characteristics of meridian phenomena

Intervention type: DEVICE
Group type: OTHER
Intervention: Laser doppler flowmetry
Description: Laser doppler flowmetry will be used to detect the microcirculatory characteristics of meridian phenomena

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser doppler flowmetry
Description: Laser doppler flowmetry will be used to detect the microcirculatory characteristics of meridian phenomena
Study: NCT02205554

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omnitram
Description: Nine 20 mg doses administered every 6 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omnitram
Description: Nine 20 mg doses administered every 6 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omnitram
Description: Nine 20 mg doses administered every 6 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: Nine 50 mg doses administered every 6 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: Nine 50 mg doses administered every 6 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: Nine 50 mg doses administered every 6 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Nine doses administered every 6 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Nine doses administered every 6 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Nine doses administered every 6 hours.
Study: NCT01330017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine HCl
Description: 10-mg immediate-release tablets, orally, up to 4 tablets per dose every 4 hours, for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine HCl
Description: 10-mg immediate-release tablets, orally, up to 4 tablets per dose every 4 hours, for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine HCl
Description: 10-mg immediate-release tablets, orally, up to 4 tablets per dose every 4 hours, for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine HCl
Description: 10-mg immediate-release tablets, orally, up to 4 tablets per dose every 4 hours, for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets, orally, up to five tablets per dose every 4 hours, for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets, orally, up to five tablets per dose every 4 hours, for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets, orally, up to five tablets per dose every 4 hours, for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets, orally, up to five tablets per dose every 4 hours, for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets, orally, up to five tablets per dose every 4 hours, for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loratadine
Description: 10-mg tablets, orally, once per day at a dose not to exceed 10 mg in a 24-hour period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loratadine
Description: 10-mg tablets, orally, once per day at a dose not to exceed 10 mg in a 24-hour period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loratadine
Description: 10-mg tablets, orally, once per day at a dose not to exceed 10 mg in a 24-hour period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loratadine
Description: 10-mg tablets, orally, once per day at a dose not to exceed 10 mg in a 24-hour period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Loratadine
Description: 10-mg tablets, orally, once per day at a dose not to exceed 10 mg in a 24-hour period.
Study: NCT02757638

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stable isotope infusion
Description: such as glycerol, D2O, tyrosine, phenylalanine, glucose, arginine, and citrulline

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stable isotope infusion
Description: such as glycerol, D2O, tyrosine, phenylalanine, glucose, arginine, and citrulline
Study: NCT03700541

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Morphine intravenous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Piritramid
Description: Piritramid intravenous
Study: NCT04615455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASCs
Description: ASCs expanded from healthy donors. The ASC product contains 22 million ASCs/ml.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cryostor CS10
Description: CryoStor® CS10 freeze medium
Study: NCT00796887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended-Release Niacin
Description: 500mg tablet once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended-Release Niacin
Description: 1000mg tablet once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet once daily
Study: NCT02363023

Intervention type: PROCEDURE
Intervention: Collect tracheal and pulmonary secretions
Description: Collect tracheal and pulmonary secretions (endotracheal aspirate, bronchoscopic and non-bronchoscopic bronchoalveolar lavage)
Study: NCT03841578

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Healthy
Description: 25g of dark chocolate (70%) will be provided to participants on Phase 1 (organoleptic assessment). On Phase 2 (gastrointestinal motility assessment), they will ingest a standard liquid meal (NutriDrink, 200ml), consisting of 10g of lactulose and 12g of fat
Study: NCT04300959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib Hydrochloride in Combination With PD1 With Gemcitabine Plus(+)Cisplatin
Description: Gemcitabine:1000mg/m2, days 1 and 8; Cisplatin: 25mg/m2, days 1 and 8； Anlotinib : 10mg po qd, days 1-14; Sintilimab: 200mg IV, day 1；~1 cycle = 3 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine Plus(+)Cisplatin
Description: Gemcitabine:1g/m2, days 1 and 8; Cisplatin: 25mg/m2, days 1 and 8；~1 cycle = 3 weeks.
Study: NCT02601807

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ActiPatch (active)
Description: Active version of the ActiPatch pulsed shortwave therapy device. Emits shortwave radiofrequency pulsed energy.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: ActiPatch (placebo)
Description: Placebo version of the ActiPatch pulsed shortwave therapy device. Emits no radiofrequency energy but otherwise appears identical to the active device.
Study: NCT04363398

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive Follow-up
Description: Trained research staff members will provide weekly support to coaches on the NMT warm-up.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Follow-up
Description: Research staff will monitor teams weekly, however no additional support for warm-up will be provided.
Study: NCT03331471

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: alveolar recruitment maneuver
Description: applying alveolar recruitment maneuver using the anesthesia machine

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional ventilation
Description: conventional ventilation using the anesthesia machine
Study: NCT03660085

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PC-PEP
Description: The 6 months at home program focuses on aerobic and strength training, pelvic floor muscle exercises, meditation, social connection, and overall healthy lifestyle practices supported with daily text message/email reminders. The aerobic (5 times/week) and strength (2 times/week) program will comprise of a single 30-minute session daily and will be individualized to each participant. Pelvic floor muscle training will include three, 10-minute sessions and mediation for 10 minutes daily. Intimacy and Connection component of PC-PEP consists of engaging in at least one form of intimacy practice prescribed, per day. Social connection will be fostered by pairing participants up with peers from the study. To encourage program compliance, study participants will receive 3 daily reminders to do their pelvic floor muscle exercises per day plus an additional motivational email daily containing helpful tips.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PC-PEP
Description: The 6 months at home program focuses on aerobic and strength training, pelvic floor muscle exercises, meditation, social connection, and overall healthy lifestyle practices supported with daily text message/email reminders. The aerobic (5 times/week) and strength (2 times/week) program will comprise of a single 30-minute session daily and will be individualized to each participant. Pelvic floor muscle training will include three, 10-minute sessions and mediation for 10 minutes daily. Intimacy and Connection component of PC-PEP consists of engaging in at least one form of intimacy practice prescribed, per day. Social connection will be fostered by pairing participants up with peers from the study. To encourage program compliance, study participants will receive 3 daily reminders to do their pelvic floor muscle exercises per day plus an additional motivational email daily containing helpful tips.
Study: NCT04002570

Intervention type: OTHER
Intervention: blood samples collection
Description: blood samples collection are performed at 4 different timepoints: preop, pre rt, week 6 rt, week 12-14 (fu) for GROUP I and GROUP II; blood samples collection are performed at 3 different timepoints: pre rt, week 6 rt, week 12-14 (fu) for GROUP I bis; blood samples collection are performed just once for control GROUP.

Intervention type: OTHER
Intervention: blood samples collection
Description: blood samples collection are performed at 4 different timepoints: preop, pre rt, week 6 rt, week 12-14 (fu) for GROUP I and GROUP II; blood samples collection are performed at 3 different timepoints: pre rt, week 6 rt, week 12-14 (fu) for GROUP I bis; blood samples collection are performed just once for control GROUP.

Intervention type: OTHER
Intervention: blood samples collection
Description: blood samples collection are performed at 4 different timepoints: preop, pre rt, week 6 rt, week 12-14 (fu) for GROUP I and GROUP II; blood samples collection are performed at 3 different timepoints: pre rt, week 6 rt, week 12-14 (fu) for GROUP I bis; blood samples collection are performed just once for control GROUP.